The ability to disseminate, invade and successfully colonise other tissues is a critical hallmark of 23
cancer that involves remodelling of the extracellular matrix (ECM) laid down by fibroblasts 1 . 24
Moreover, Cancer-Associated-Fibroblasts (CAFs) produce key growth factors and cytokines as 25 components of the ECM that fuel tumour growth, metastasis and chemoresistance, and immune 26 response [2] [3] [4] . ECM changes also predict prognosis in pancreatic 5 and colorectal cancers 6, 7 . Here, 27
we examine the landscape of ECM-gene dysregulation pan-cancer and find that a subset of ECM 28 genes is (i) dysregulated specifically in cancer, (ii) adversely prognostic, (iii) linked to TGF-beta 29 signalling and transcription in Cancer-Associated-Fibroblasts, (iv) enriched in immunologically 30 active cancers, and (v) predicts responses to Immune checkpoint blockade better than mutation 31 burden, cytolytic activity, or an interferon signature, thus identifying a novel mechanism of 32 immune evasion for patient stratification in precision immunotherapy and pharmacological 33
modulation. 34
Initially, to study ECM gene dysregulation across cancers, we defined a transcriptional signature to 35 distinguish malignant (n = 8043) and normal samples (n = 704) accounting for tumour type (n = 15) 36 from TCGA and tested for enrichment of an ECM-associated gene-set we curated based on gene 37 ontology terms (Table S1 , Figure S1A ). This identified 58/239 ECM genes to be cancer-associated 38 (hereby Cancer-associated-ECM genes/ C-ECM genes) (Table S2) , representing significant enrichment 39 amongst both upregulated (OR = 3.51, p < 3.9e-8) and downregulated (OR = 2.57, p = 3e-5, Fisher's 40 Exact Test) genes in malignant tissues ( Figure 1A ). Upon summarisation using ssGSEA (single sample 41 Gene Set Enrichment Analysis) scores 8, 9 , these show broad variation across tumour types ( Figure 1B , 42
Figure S1B-C). We then performed a Cox regression based on quartile-thresholded C-ECM scores 43
with AJCC stage and tumour-type as strata highlighted to examine the prognostic impact of this 44 dysregulation, which showed upregulated C-ECM genes to be significantly prognostic ( Figure 1C -D, 45 HR = 1.73, p < 6.3e-7 for top vs bottom quartile) while downregulated genes were not ( Figure S1D ), 46
suggesting that the variation we observed in C-ECM gene transcription is clinically relevant. First, tumour purity estimated using ABSOLUTE 11 were inversely correlated for both C-ECM up and 54 down scores (Figure 2A, S2A) . Second, projecting the expression signature onto microdissected 55
Ovarian cancer stroma, matched epithelium, and their normal counterparts 12 (GSE40595) resulted 56 in clustering by sample type with strong stromal expression ( Figure 2B ). Additionally, probes 57 differentially expressed between cancer epithelium and stroma, and between cancer and normal 58 stroma, were significantly enriched for both C-ECM-up and down genes ( Figure 2C ) for the former, 59
and C-ECM-up genes for the latter. Third, deconvolution analysis using MethylCIBERSORT implicated 60
CAFs, CD8 T-cells, and CD14-monocytes as directly correlated with C-ECM signature scores ( Figure  61 2D). Importantly, upregulated C-ECM genes (ssGSEA scores) showed a positive correlation to the 62 inferred CAF frequency in most TCGA cancer types ( Figure S2B ). We also validated these inferences 63 of cellular association using transcript levels of well-known marker genes (Cytolytic activity 64 (geometric mean of GZMA, PRF1) and CD8A expression for CD8 T-cells, ACTA2 for CAFs and CD14 for 65 monocytes, Figure S2C ), whereupon we noticed strong, consistent, agreement. 66
Finally, as an ultimate test of a CAF origin, we examined a dataset of single cell transcriptomes from 67 head and neck cancers (GSE103322) 13 and found markedly higher expression of C-ECM genes in 68 CAFs, which clustered together when the signature was projected onto the dataset ( Figure 2E) . 69 70 Indeed, C-ECM up and down ssGSEA scores were significantly elevated in CAFs compared to other 72 cell types ( Figure 2F ), which we also independently verified in an additional colorectal cancer single-73 cell RNAseq dataset (GSE81861, Figure S2D ) 14 . Therefore, C-ECM profiles appear to be generated 74 through the modulation of transcriptional profiles in CAFs specifically in malignancy. 75
Then, given that C-ECM scores correlate with CD8 T-cells and cytolytic activity (CYT) ( Figure 2D and 76 Figure S2C ), and the fact that C-ECM up-scores are adversely prognostic despite the positive 77 prognostic impact of CYT 15 , we postulated that the C-ECM up-score may be enriched in 78
immunologically 'hot' tumours, and our subsequent analyses uncovered robust evidence for this 79 association using multiple orthogonal approaches. Accordingly, the C-ECM-up score was positively 80 correlated with mutational burden (Rho = 0.23, p < 2.2e-16) while the down-signature was 81 negatively correlated (Rho = -0.21, p < 2.2e-16) ( Figure 3A) . 82
Associations between C-ECM scores and Class I neoantigen burden were also concordant (Rho = 0.21 83 and -0.21, p < 2.2e-16, Figure S3A ) and so were associations between C-ECM scores and 84
Microsatellite Instability, an immunotherapy biomarker per se 16 ( Figure S3B ). Additionally, we 85 assessed macrophage polarisation using CIBERSORT 17 and found that the ECM-up signature was 86 associated with a greater fraction of M1 relative to M2 (immunosuppressive) macrophages (Figure  87 S3C). Finally, we found that multiple immune checkpoints, including IDO1, B7-H3 and PD-L2 were 88 overexpressed in samples in the top quartile of the C-ECM up-score distribution relative to bottom 89 quartile cancers after adjusting for tumour type (2FC, FDR < 0.01), indicating the upregulation of 90 adaptive resistance mechanisms to immune-cell mediated destruction ( Figure S3D ). Moreover, these 91 themes were broadly reinforced by IPA Canonical Pathway Analysis, which identified enrichment for 92 inflammatory processes and adaptive immune responses enriched in samples in the top quartile of 93 the C-ECM up-score ( Figure 3B) . 94
Next, since our data suggest that the C-ECM-up signature was generated by CAFs, and not by normal 96 stroma, we endeavoured to find putative drivers responsible for this dysregulation. IPA Causal 97
Network Analysis, after restriction to candidate regulators which by themselves differentially 98 expressed between C-ECM-up top and bottom quartiles, identified TGF-β as one of the most 99 activated regulators ( Figure S3E) As TGF-β is known to exert both pro-fibrotic and anti-proliferative effects, we decided to examine if 115 enrichment for the C-ECM-up signature exerted specific adaptive constraints on the evolution of 116 cancer genomes using TCGA data. Linear modelling implicated multiple genes after controlling for 117 tumour type with known associations with TGF-β signalling from candidates positively selected in 118 cancer 20 . 119
Notable candidates included TP53, SMAD4, BRAF, ACVR1B and NF1/2 ( Figure 3E ). We also implicated 120 18/111 significant GISTIC 21 peaks ( Figure 3F ), most notably MYC amplification (8q24.1) ( See Table  121 S7 for detailed description of supporting literature), collectively confirming the hypothesized 122 adaptation for TGF-β activation. showed that models with C-ECM ssGSEA scores significantly outperformed those involving cytolytic 131 activity, a T-cell inflamed signature, and mutation load alone ( Figure 4C, S4A) . Moreover, the 132 aggregate score is comparable to a random forest fit with individual C-ECMs. Importantly, TGFB1 133 expression alone does markedly worse than C-ECM based models, suggesting the presence of CAFs 134 are required to convert TGFB1 expression to an ICB-resistant phenotype through transcriptional 135 modulation. Finally, restricted hypothesis testing using limma-trend found 19 C-ECM genes 136 overexpressed at FDR < 0.1 ( Figure 4D ) between responders and nonresponders, defining a practical 137 signature for clinical application ( Figure S4B) . 138
Given CAF-depletion per se is paradoxically associated with worse outcomes between ICB responders and nonresponders after controlling for study-specific variation. 253
